CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 170 enrolled
Drug / intervention
EMPOWER-EDbehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04572750
NCT04572750N/ACompleted

Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention

VA Office of Research and Development·interventional·Posted Oct 1, 2020·Updated Jan 23, 2026

In Brief

A clinical study evaluating EMPOWER-ED for Taking Benzodiazepines for Any Reason for 3 Months and Benzodiazepine Dependence. Completed, enrolled 170 participants across 1 site.

Detailed Summary

Benzodiazepines (e.g., Ativan, Xanax) are widely prescribed medications that are used mainly to treat anxiety and sleeping difficulties. Long-term use of benzodiazepine carries risks of physical dependence, addiction, falls and other accidents, and problems in thinking/concentrating. Researchers in Canada developed a printed self-help packet that enabled many individuals to reduce or cease taking benzodiazepines on their own. This study is designed to tailor that packet to the Veteran population, convert it to an app that people can use on their laptop or smart phone, and test whether the app helps promote benzodiazepine prescribing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedOct 1, 2020
Enrollment StartJun 1, 2022
Primary CompletionJul 3, 2024
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.8 years ago

Interventions

EMPOWER-EDbehavioral

An electronic app that runs on a variety of platforms and provides education and tools designed to promote self-driven reduction of benzodiazepines.